Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 10, 2011, Pages 2120-2122

  De Oliveira Almeida, V C ^a,b   De Souza Ferreira, A C ^b   Ribeiro, D D ^a   Gomes Borges, K B ^a   Salles Moura Fernandes, A P ^a   Brunialti Godard, A L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Hermes Pardini   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AZATHIOPRINE; CARBAMAZEPINE; CYSTEINE; DIAZEPAM; FLUOXETINE; LEVOTHYROXINE; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PHENOBARBITAL; PREDNISONE; PROPRANOLOL; SIMVASTATIN; THREONINE; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG USE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECESSIVE INHERITANCE; THROMBOPHILIA;

ANTICOAGULANTS; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; THROMBOPHILIA; WARFARIN;

EID: 80053430583     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04452.x     Document Type: Letter

References (15)

1. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 2005; 20: 391-414.
2. Leschziner GD, Andrew T, PIrmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007; 7: 154-79.
3. Sussman NL, Waltershied M, Butler T, Cali JJ, Riss T, Kelly JH. The predictive nature of high throughput toxicity screening using a human hepatocyte cell line. Cell Notes 2002; 3: 7-10.
4. FDA approves updates warfarin (Coumadin) prescribing information: new genetic information may help providers initial dosing estimates of the anticoagulation for individual patients. 108967.htm; Accessed 15 August 2010.
5. Sinxadi M, Blockman M. Warfarin resistance. Cardiovasc J Afr 2008; 19: 215-7.
6. Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, ken-Dror G, Almog S, Gak E. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109: 2477-80.
7. Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, Morse C, Shearer MJ, Mumford AD. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 2008; 6: 1663-70.
8. Sabol BJ, Basa RR, Wilkins CE. Malabsorption-associated warfarin resistance. Am J Health Syst Pharm 2009; 66: 1548-53.
9. Gilman GA, Goodman LS, Rall TW, Murad F. Goodman and Gilman's Pharmacological Basis of Therapeutics. Rio de Janeiro: Guanabara Koogan, 2003.
10. Gonzalez TP, Schiengold M, Chies JAB. Implicações clínicas dos polimorfismos do gene de resistência a múltiplas drogas MDR1 (ABCB1). Revista Brasileira de Biociências 2006; 4: 27-38.
11. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy japanese subjects. Pharm Res 2001; 18: 1400-4.
12. Wadelius M, Sorlin K, Wallerman O, Karlsson J, Yue Q-Y, Magnusson PKE, Wadelius C, Melhus H. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004; 4: 40-8.
13. Santos PCJL, Soares RAG, Santos DBG, Nascimento RM, Coelho GLLM, Nicolau JC, Mill JG, Krieger JE, Pereira AC. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet. 2011; 12: 13.
14. Rodrigues AC, Rebecchi IMM, Bertolami MC, Faludi AA, Hirata MH, Hirata RDC. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res 2005; 38: 1389-97.
15. Saraeva RB, Paskaleva ID, Doncheva E, Eapá CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther 2007; 32: 641-9.